Valuation: Everest Organics Limited

Market Cap 2.13B 22.17M 19.69M 18.41M 16.78M 31.59M 32.02M 223M 86.23M 1.09B 83.23M 81.43M 3.49B P/E 2025
-190x
P/E 2026 35.7x
Enterprise Value 2.63B 27.29M 24.24M 22.67M 20.65M 38.88M 39.42M 274M 106M 1.34B 102M 100M 4.3B EV / Sales 2025
1.79x
EV / Sales 2026 1.25x
Free-Float
23.1%
Yield 2025 *
-
Yield 2026 -
1 day-0.77%
1 week-8.24%
Current month-0.77%
1 month-20.65%
3 months-12.08%
6 months-0.50%
Current year-56.54%
1 week 213.45
Extreme 213.45
257
1 month 213.45
Extreme 213.45
284
Current year 197
Extreme 197
536.4
1 year 197
Extreme 197
536.4
3 years 110
Extreme 110
536.4
5 years 95
Extreme 95
536.4
10 years 44.45
Extreme 44.45
536.4
Manager TitleAgeSince
Chief Executive Officer 48 -
Director of Finance/CFO 59 2015-09-27
Director TitleAgeSince
Director/Board Member 71 2024-11-12
Director/Board Member - 2026-08-13
Director/Board Member 47 2007-09-28
Change 5-day change 1-year change 3-year change Capi.($)
-0.77%-8.24%-45.85%+84.55% 22.43M
-0.62%-2.71%+39.30%+114.07% 1,031B
-2.30%-4.44%+39.03%+66.07% 638B
-0.63%-1.96%+6.36%+74.38% 462B
-1.03%-2.82%+59.56%+39.69% 359B
-0.03%-3.96%+23.63%+39.35% 335B
-1.58%-0.76%+13.50%+25.77% 273B
-2.02%-2.97%-3.25%+8.38% 253B
-3.38%+0.30%+36.44%+51.54% 228B
-1.04%-1.46%+32.70%+96.82% 185B
Average -1.34%-2.28%+20.14%+60.06% 376.39B
Weighted average by Cap. -1.25%-1.89%+30.52%+69.18%

Financials

2025 2026
Net sales 1.6B 16.61M 14.76M 13.8M 12.57M 23.67M 24M 167M 64.62M 815M 62.37M 61.02M 2.62B 1.97B 20.43M 18.15M 16.97M 15.46M 29.11M 29.51M 205M 79.47M 1B 76.7M 75.04M 3.22B
Net income -12.9M -134K -119K -111K -101K -191K -194K -1.35M -521K -6.57M -503K -492K -21.11M 55.46M 576K 512K 479K 436K 821K 832K 5.79M 2.24M 28.25M 2.16M 2.12M 90.73M
Net Debt 412M 4.28M 3.8M 3.56M 3.24M 6.1M 6.19M 43.04M 16.66M 210M 16.08M 15.73M 675M 493M 5.12M 4.55M 4.25M 3.87M 7.29M 7.39M 51.44M 19.91M 251M 19.22M 18.8M 806M
Logo Everest Organics Limited
Everest Organics Limited is engaged in the business of manufacturing of active pharmaceutical ingredients (API) and intermediaries. It is involved in the manufacturing of bulk drugs. The Company’s API products include Omeprazole, Pantoprazole Sodium Sesquihydrate, Esomeprazole Magnesium Trihydrate, Esomeprazole Magnesium Dihydrate, Esomeprazole Sodium, Omeprazole Sodium, Omeprazole Magnesium, Fenofibrate, Tamsulosin Hcl, and Dexlansoprazole. Its products under development include Remdesivir, Molnupiravir, Carbidopa, Acotiamide HCL, and Apixaban. Its intermediates products include Ethyl 2-(4-Hydroxyphenyl)-4-Methyl-5-Thiazolecarboxylate, Ethyl 2-(3-Formyl-4-Hydroxyphenyl)-4-Methylthiazole-5- Carboxylate, Ethyl 2-(3-Formyl-4-Isobutoxyphenyl)-4-Methylthiazole-5-Carboxylate, Ethyl 2-(3-Cyano-4-Isobutoxyphenyl)-4-Methyl-5- Thiazolecarboxylate, 2-Chloromethyl-4-Methoxy-3-Methyl-Pyridine Hydrochloride, and 5-(1H-Pyroll-1-yl)-2-Mercaptobenzimidazole, among others.
Employees
316
Date Price Change Volume
26-10-01 ₹219.80 -0.77% 671
26-09-30 ₹221.50 -0.54% 843
26-09-29 ₹222.70 +3.27% 4,007
26-09-28 ₹215.65 -5.83% 2,428
26-09-25 ₹229.00 -4.40% 810
  1. Stock Market
  2. Stocks
  3. EVERESTO6 Stock